In brief: Eqitx, Stirling Products
Monday, 12 July, 2004
Two Perth-based biotechs have made key executive appointments.
Drug development company Eqitx (ASX:EQX) has former CSL and Amrad business development executive Joy Hewitt as its chief commercialisation officer.
At CSL, Hewitt was R&D and pharmaceuticals business development manager, where her responsibilities included commercialising CSL projects, evaluating and securing R&D opportunities, and in-licensing pharmaceutical products for domestic and NZ markets. Eqitx said Hewitt had also acted as a consultant to Australian research, biotech and medical organisations.
Animal growth promoter specialist Stirling Products (ASX:STI) has appointed Murray Ward, a stockbroker with 20 years' experience, as an executive director.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
